How much cash does Spyre Therapeutics, Inc. generate?

Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.

Where does Spyre Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Spyre Therapeutics, Inc. SYRE Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$155.2M+25.4%	-$208.02M+38.6%	-$338.79M-304%	-$83.82M-27.4%
Stock-based compensation	$37.61M-16.1%	$44.85M+74.7%	$25.68M+261%	$7.11M-11.5%
Gain (loss) on sale of assets	$0—	$0+100%	-$915K—	——
Change in accounts payable	$8.24M+3,682%	-$230K—	——	-$2.64M-348%
Change in accrued liabilities	——	$14.61M—	——	——
Change in other assets	$12.82M—	——	——	——
Change in other liabilities	-$589K+96.3%	-$15.98M-565%	-$2.4M—	——
Net cash from operating activities	-$169.25M-7.5%	-$157.41M-57.6%	-$99.91M-24.7%	-$80.14M-43.6%
Purchases of investments	$522.21M-12.9%	$599.25M+259%	$166.8M+322%	$39.5M-70.3%
Proceeds from maturities/sales of investments	$371.74M+51.1%	$245.97M+516%	$39.9M-58.7%	$96.55M-13.0%
Acquired in-process research and development	——	——	$15M—	——
Net cash from investing activities	-$143.48M—	——	-$108.39M-290%	$57.01M—
Proceeds from issuance of common stock	$3.31M—	——	$84.56M+97.1%	$42.9M—
Net cash from financing activities	$309.03M-24.8%	$410.91M+10.0%	$373.61M—	——
Net increase (decrease) in cash	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$8.09M-29.1%	$11.4M+392%	$2.32M+609%	$327K+160%
Acquired in-process research and development	——	$0—	——	$0—
Gain (Loss) on Derivative Instruments, Net, Pretax	——	——	——	——
Accounts payable	$8.24M+3,682%	-$230K—	——	——
Accrued expenses and other liabilities	——	$14.61M—	——	——
Increase Decrease In Other Accounts Payable	-$589K+96.3%	-$15.98M-565%	-$2.4M—	——
Increase (Decrease) in Prepaid Expense and Other Assets	$12.82M—	——	——	——
Interest proceeds from maturities of zero coupon U.S. Treasury Bills	$2.13M+66.0%	$1.28M—	——	$0—
Proceeds From Sale And Maturity Of Available For Sale Securities	$371.74M+51.1%	$245.97M+516%	$39.9M-58.7%	$96.55M-13.0%
Payment For Deferred Offering Costs	——	$407K—	$0—	$0—
Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs	——	——	$0—	$0—
Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs	$296.38M+37.3%	$215.86M—	$0—	$0—
Proceeds from exercises of stock options and other stock issuances	$3.31M-56.0%	$7.51M+1,755%	$405K—	——
Other, net	$0-100%	$1K+106%	-$16K—	——
Allocation of deferred offering costs against proceeds of issuance of common stock	——	——	——	$0—
Issuances of common stock from employee benefit plans receivable	——	——	$202.18M—	$0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Spyre Therapeutics, Inc. generate?: Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
Where does Spyre Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.